Skin Booster Combination Protocols: Sequencing Polynucleotides with HA Boosters

Once a clinic stocks both modalities, the next question is always sequencing; the answer is more clinical than commercial.

Polynucleotides and hyaluronic acid bio-remodelling boosters are now standard across most UK aesthetic stocklists. Both improve skin quality, but they do so through distinct mechanisms. When practitioners combine them without a clear protocol rationale, they risk compounding cost without compounding benefit, or worse, creating an inflammatory overlap that delays visible results. This article sets out the clinical basis for combining skin boosters, the published evidence that supports sequenced biostimulation, and practical protocol frameworks by indication.

Why Combine Polynucleotides and HA Bio-Remodelling Boosters

Polynucleotides (PDRN or PN, derived from salmon or trout DNA) act primarily through adenosine A2A receptor agonism. This pathway upregulates fibroblast proliferation and migration, stimulates procollagen and elastin synthesis, and suppresses inflammatory cytokines including TNF-alpha and IL-6 (Mastropasqua et al, Scientific Reports, 2020; https://www.nature.com/articles/s41598-020-61952-w). The net effect is structural regeneration driven at the cellular level over a course of weeks.

High-concentration HA bio-remodelling products such as Profhilo (IBSA) deliver a different mechanism. Profhilo combines free high- and low-molecular-weight HA in a patented thermal cross-linking (NAHYCO) process. Rather than volumising, it disperses widely through the dermis and hypodermis to hydrate, stimulate fibroblasts, and promote adipocyte differentiation. The collagen and elastin stimulation is real but comparatively slower and more dispersed than a targeted polynucleotide course.

Combining the two is logical precisely because the mechanisms are additive rather than duplicative. Polynucleotides drive fibroblast activity and repair at a cellular receptor level; HA bio-remodelling sustains hydration and structural scaffolding for that new collagen to populate. You are not doing the same thing twice. You are giving the tissue two different signals that support the same outcome: improved dermal architecture.

Browse our full range of polynucleotide products and skin boosters to compare formulations by indication.

The Evidence for Combination Biostimulation

Standalone evidence for each modality is well established. Mastropasqua et al demonstrated that PDRN treatment of human fibroblast cultures produced statistically significant increases in type I procollagen and fibronectin compared to controls, with the effect mediated through A2A receptor activation rather than generic growth factor stimulation. This mechanism is relevant because it is receptor-specific and largely independent of the inflammatory cascade, which matters when combining treatments.

For Profhilo specifically, IBSA's published clinical data shows a statistically significant increase in skin laxity improvement scores and patient satisfaction at 12 weeks following two sessions spaced one month apart. The BAP (Bio Aesthetic Points) injection technique was developed partly to reduce bruising and to optimise dispersal across the five anatomical depots on each side of the face.

Direct head-to-head trials on combined polynucleotide and HA bio-remodelling protocols remain limited in the peer-reviewed literature at this time. The evidence base for sequenced combination is currently built from mechanistic rationale, individual modality RCTs, and growing real-world case series. Practitioners should document their own outcomes and reference established clinical guidance such as that published by the British College of Aesthetic Medicine (BCAM) when discussing combination approaches with patients.

Sequencing Principles: Same Session vs Spaced, Which First

The central question practitioners ask is whether polynucleotides and HA boosters can be administered in the same session, and if not, which should come first.

The practical consensus, supported by the mechanistic profile of each product, is as follows:

• Same-session use is feasible for thin-tissue areas such as the periorbital zone and neck, where polynucleotides are the primary driver and a low-volume HA booster such as Sunekos 200 (that targets the periorbital dermis directly) is used as an adjunct. The inflammatory burden of intradermal polynucleotide injection is low, and the risk of product displacement by a simultaneous low-volume HA booster is minimal provided injection planes are respected.
• Staggered sessions are preferred for full-face protocols involving higher-volume HA bio-remodelling agents such as Profhilo 2 ml. The rationale is practical rather than mechanistic: higher injection volumes create a transient localised papule at the BAP points that resolves over 24 to 48 hours. Layering polynucleotide injections into the same tissue in the same session increases patient discomfort without clear clinical benefit and complicates outcome attribution.
• Start with polynucleotides when the primary goal is repair or regeneration (photoaged, thin, or structurally compromised skin). Polynucleotides prime the fibroblast population and reduce baseline inflammation. Introducing HA bio-remodelling one to two weeks later gives the stimulated fibroblasts a hydrated scaffold environment to work within.
• Start with HA bio-remodelling when the primary goal is laxity and hydration in a patient with adequate skin quality. Profhilo or a comparable product can restore baseline dermal hydration and elasticity, after which polynucleotides can be used to sustain and deepen the regenerative response.

There is no single correct answer, and the sequencing decision should be documented in the patient record with explicit clinical justification.

Example Protocols by Indication

The table below outlines suggested sequencing frameworks. These are starting-point frameworks and must be adapted to individual patient assessment. All sessions assume standard pre-treatment consultation, contraindication screen, and written consent per BCAM and HEE guidance.

For practitioners using dermal filler in the same patient, the general rule is to complete the biostimulation course before adding structural filler, or to maintain a four-week gap between deep filler and any superficial biostimulator to avoid inflammatory cross-reaction at the injection site.

Interval and Course Planning

Course planning for combination protocols needs to account for the different timelines of each modality's biological response.

Polynucleotides typically require three to four sessions spaced two to three weeks apart before clinical improvement is visible to the practitioner and the patient. The collagen remodelling phase continues for eight to twelve weeks after the final session. Maintenance is generally one session every three to four months.

Profhilo's published protocol is two sessions four weeks apart, with a review at eight weeks. Visible improvement in laxity and skin quality is typically noted at the eight-week assessment. Maintenance is generally every six months, though patient age, lifestyle, and degree of initial improvement influence this.

When planning a combined course, the total active treatment window is therefore approximately three to four months from first polynucleotide session to final HA booster session. Communicating this timeline clearly at consultation is essential for managing expectations and retaining patients through the course rather than losing them after two sessions when results are still consolidating.

Patient Selection and Managing Expectations

Combination protocols are best suited to patients who:

• Present with established skin quality concerns (photoaging, fine lines, skin thinning, mild laxity) rather than primary volume deficit
• Are willing to commit to a multi-session course spanning two to four months
• Have realistic expectations: combination biostimulation produces progressive, naturalistic improvement, not an immediate visible change after a single session
• Are motivated by skin health and long-term structural improvement rather than immediate visible correction

Patients expecting rapid results similar to structural filler are not good candidates for combination booster courses without careful expectation management at consultation. It is worth showing clinical photography from weeks four and eight to illustrate how the response evolves.

For younger patients (mid-twenties to mid-thirties) with no significant skin quality deficit, a standalone polynucleotide course or standalone HA booster is usually sufficient. Combination protocols carry their greatest benefit in the 40-plus cohort and in patients with visible photoaging, post-acne scarring, or skin compromised by systemic factors.

Contraindications and Cost and Downtime Considerations

Each modality carries its own contraindication profile, and these apply additively in combination:

• Polynucleotides: active autoimmune conditions, known fish allergy (salmon-derived PDRN), anticoagulant therapy (relative, risk-benefit assessment required), active infection at the treatment site, pregnancy and breastfeeding
• HA bio-remodelling: allergy to HA or product excipients, active skin infection at the injection site, history of severe allergic reactions, bleeding disorders (relative), pregnancy and breastfeeding

In practice, a patient who is safe for one modality is usually safe for the other. The combined protocol does not create new contraindications, but the practitioner should document a full contraindication screen for both products at the initial consultation and update it at each session.

On cost: a full combined course (three polynucleotide sessions plus two Profhilo sessions) typically represents two to three times the cost of a standalone two-session Profhilo course. Practitioners should present this transparently, ideally with a phased payment option or a modular approach that allows the patient to start with polynucleotides and add HA bio-remodelling at review. Packaging without justification is a compliance concern under current ASA guidance on claims.

Downtime is additive but modest. Polynucleotide injections produce minimal erythema and occasional transient papules that resolve within a few hours. Profhilo BAP injections can produce small bumps at the five depot points per side that resolve within 24 to 48 hours. Patients combining both in a staggered protocol should be advised to allow 48 hours before important events after each session.

Key Takeaways

• Polynucleotides and HA bio-remodelling boosters work through different, complementary mechanisms and can be rationally combined.
• Same-session use is feasible for thin-tissue or periorbital protocols; staggered sessions (2 to 4 weeks apart) are preferred for full-face high-volume HA bio-remodelling.
• Start with polynucleotides when the primary goal is cellular repair and regeneration; start with HA bio-remodelling when baseline hydration and laxity are the primary concern.
• Allow 8 to 12 weeks for the full remodelling response before assessing the outcome of a combined course.
• Patient selection and expectation management are as important as product selection; combination protocols need motivated, course-committed patients.
• Every clinical claim in your consultation and consent documentation should be traceable to a named source.
• Document the sequencing rationale in the patient record for defensibility.

References

• Mastropasqua et al. PDRN and A2A receptor-mediated fibroblast stimulation. Scientific Reports, Nature, 2020.
• IBSA Institut Biochimique SA. Profhilo product information. IBSA, 2024.
• British College of Aesthetic Medicine (BCAM). Dermal Fillers. BCAM Patient Information.
• Croma Pharma. PhilArt polynucleotide product information. Croma Pharma GmbH.

Reviewed for clinical accuracy under the supervision of our Superintendent Pharmacist, Alicia Barker (GPhC 2241860). Longeva Pharmacy is a GPhC-registered pharmacy (registration 9012378) operating under MHRA WDA(H) licence 59619. Information is intended for licensed UK practitioners and does not replace individual clinical judgement.